Recent news on Hyzaar

Consumers Beware Of The Internet: Americas Watchdog Declares War ...  -  May 21, 2007
Emediawire (press release),Preliminary laboratory results to date have found counterfeits of the following drug products: Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (known as

Everybody is Satis  -  May 15, 2007
Journal lycéen,It stimulates neuron bundles to release a particular enalaprilgroup of neurotransmitters known as hyzaar ; these include flextra , flexeril (also known as

Seeds, Foreign Markets Nourish DuPont  -  Apr 24, 2007
Smartmoney.comMeanwhile, the company warned analysts that income from hypertension drugs Cozaar and Hyzaar will take a significant "step-down" in 2010 and eventually fall

Merck posts higher net, affirms 2007 forecast  -  Apr 19, 2007
MarketWatchHypertension medications Cozaar and Hyzaar, No. 2 among Merck's best-selling product lines, saw combined quarterly sales of $798 million, up 14%.

Merck Net Up 12% Amid Broad Sales Gains  -  Apr 19, 2007
Smartmoney.comHypertension medications Cozaar and Hyzaar saw combined quarterly sales of $798 million, up 14%. Revenue from the company's joint venture with

Merck 1Q profits up 12%  -  Apr 20, 2007
newratings.comSales of Merck’s popular asthma drug, Singulair, rose 25% to $1 billion and the combined sales of hypertension drugs Cozaar and Hyzaar came in at $798

Merck net jumps 12 percent  -  Apr 19, 2007
BusinessWeekCompanion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil -- Merck's vaccine to prevent infection by the

Merck 1Q profit jumps 12 percent  -  Apr 19, 2007
Ottawa Recorder,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent. Sales of Gardasil, a vaccine that prevents infection from a

Merck net jumps 12 percent  -  Apr 19, 2007
Leading The Charge,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil — Merck‘s vaccine to prevent infection by the

Merck net jumps 12 percent  -  Apr 19, 2007
Euro2day,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil -- Merck''s vaccine to prevent infection by the

Bristol seeks expanded blood pressure drug use  -  Apr 17, 2007
CNNMoney.comAvalide and Avapro compete with Merck's (down $0.34 to $49.98, Charts) blood pressure drugs Hyzaar and Cozaar, which together totaled $3.2 billion in 2006

Merck Reports Strong Financial Results for First-Quarter 2007  -  Apr 19, 2007
Business Wire (press release),Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR 2 , were $798 million for the first quarter, representing an increase of 14% compared

Merck Reports Strong Financial Results for First-Quarter 2007  -  Apr 19, 2007
PharmaLive.com (press release),COZAAR and HYZAAR are among the world's leading angiotensin receptor blockers, the fastest growing class in the antihypertensive market.

Two Are Named Pharmaceutical Sciences Outstanding Alumni  -  Apr 20, 2007
UK News,He acted as a technology transfer leader for Sustiva® tablet and contributed to the development of Cozaar/Hyzaar tablets. Throughout his career, he has

Merck's Q1 profit rises  -  Apr 20, 2007
Pharma Times (subscription),Also helping Merck obtain double-digit earnings were the angiotensin receptor blockers, Cozaar (losartan) and Hyzaar (losartan plus hydrochlorothiazide),

Update -- Strong Sales Boost Merck  -  Apr 19, 2007
Forbes,According to a Goldman Sachs research note released on Thursday, Gardasil, Singulair, an asthma and allergy drug, and Cozaar/Hyzaar, an antihypertensive

Merck net jumps 12 percent  -  Apr 19, 2007
Kansas City Star,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil - Merck's vaccine to prevent infection by the

Merck net jumps 12 percent  -  Apr 19, 2007
Houston Chronicle,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil — Merck's vaccine to prevent infection by the

Merck Net Jumps 12 Percent  -  Apr 19, 2007
Houston Chronicle,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil _ Merck's vaccine to prevent infection by the

Merck profit rises as new drugs fill void  -  Apr 19, 2007
ReutersSingulair sales jumped 25 percent to $1 billion, while combined sales of hypertension drugs Cozaar and Hyzaar rose 14 percent to $798 million.

READINGTON: Merck & Co. net rises 12 percent  -  Apr 19, 2007
Bridgewater Courier News,Companion blood pressure drugs Cozaar and Hyzaar brought in $798 million, up 14 percent, while Gardasil — Merck’s vaccine to prevent infection by the

Bristol seeks expand blood pressure drug use  -  Apr 17, 2007
CNNMoney.comAvalide and Avapro compete with Merck's (down $0.35 to $49.97, Charts) blood pressure drugs Hyzaar and Cozaar, which together totaled $3.2 billion in 2006

Profit forecast lifted; court rulings could ease Vioxx litigation ...  -  Apr 13, 2007
MarketWatch...only from such older products as Fosamax and Cozaar/Hyzaar but also from such newer drugs as Januvia for diabetes and the vaccines RotaTeq and Gardasil.

Merck shares jump on forecast, Vioxx court updates  -  Apr 13, 2007
MarketWatchTh analysts said they seem higher growth not only from such older products at Fosamax and Cozaar/Hyzaar, but also from such newer drugs as Januvia for

Committee on Commerce, Science, and Transportation  -  Mar 7, 2007
FDA.gov...of the following drug products: Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (known as Zetia in the United States), Crestor, Celebrex, Arimidex,

Merck Announces 2006 Financial Results that Demonstrate Solid ...  -  Jan 30, 2007
Business Wire (press release),Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR*, were $865 million for the fourth quarter, representing an increase of 11% compared

Merck’s Revenue Increases, but Charges Eat Into Profit  -  Jan 30, 2007
New York Times,Sales of Singulair and of the related blood pressure drugs Cozaar and Hyzaar both rose by double digits, but sales of Merck’s other top drug, Fosamax,

Merck, Wyeth Shares Fall After Reports  -  Jan 30, 2007
CBS News,Sales of Singulair and blood pressure drugs Cozaar and Hyzaar rose by double digits, but Fosamax saw flat sales. "On a continuing operations basis,

Merck, Wyeth Shares Fall After Reports  -  Jan 30, 2007
ABC News...which prevents cervical cancer. Sales of Singulair and blood pressure drugs Cozaar and Hyzaar rose by double digits, but Fosamax saw flat sales.

Merck fourth-quarter net drops 58 percent on charges  -  Jan 30, 2007
Boston Herald,Sales of Singulair and of related blood pressure drugs Cozaar and Hyzaar both rose by double digits, but Merck’s other top drug, Fosamax, saw flat sales.

Merck reports lower earnings  -  Jan 30, 2007
MarketWatchMerck's high blood pressure medications Cozaar and Hyzaar had combined sales of $865, up 11% from last year. Combined sales of the company's cholesterol

Merck, Wyeth shares fall after reports  -  Jan 30, 2007
Hemscott,Sales of Singulair and blood pressure drugs Cozaar and Hyzaar rose by double digits, but Fosamax saw flat sales. 'On a continuing operations basis,

Merck's Profit Plunges  -  Jan 30, 2007
6abc.com,Sales of Singulair and of related blood pressure drugs Cozaar and Hyzaar both rose by double digits, but Merck's other top drug, Fosamax, saw flat sales.

Merck Q4 Profit Declines 58% On Charges, Dip In Zocor Sales; EPS ...  -  Jan 30, 2007
Trading Markets,While hypertension treatment Cozaar/Hyzaar is expected to sell in the range of $3.1-$3.4 billion, sales from vaccines is expected to be $2.8-$3.2 billion.

Merck Q4 2006 Earnings Call Transcript  -  Jan 30, 2007
Seeking Alpha,Cozaar and Hyzaar increased 11% year-over-year. In addition, total sales of Merck's other promoted medicines and vaccines were collectively $2 billion for

Merck Backs FY06 EPS Outlook, Guides FY07; Reaffirms Plan To ...  -  Dec 6, 2006
Trading Markets,For 2006, the Merck expects worldwide sales of Singulair in the range of $3.4-$3.7 billion, sales of Cozaar/Hyzaar in the range of $3-$3.3 billion, sales of ...

Merck & Co keeps profit forecasts conservative for 2007  -  Dec 7, 2006
Pharma Times (subscription),...better-established products: $3.7-$4 billion for asthma drug Singulair (montelukast); $3.1-$3.4 billion for the antihypertensive Cozaar/Hyzaar (losartan); and ...

Merck Remains Confident in Future Growth as it Executes on New ...  -  Dec 12, 2006
Genetic Engineering News (press release),WORLDWIDE PRODUCT 2007 SALES SINGULAIR (Respiratory) $3.7 to $4.0 billion COZAAR/HYZAAR (Hypertension) $3.1 to $3.4 billion Vaccines (as recorded by Merck & Co ...

Merck backs forecast for year  -  Dec 6, 2006
MarketWatchIts Cozaar/Hyzaar hypertension drug is targeting $3 billion to $3.3 billion in 2006 sales, and 2007 sales $3.1 billion to $3.4 billion. ...

Merck reaffirms outlook, sets '07 view  -  Dec 6, 2006
BusinessWeek...of its key products will be about $3.85 billion for respiratory drug Singulair, $3.25 billion for companion blood pressure drugs Cozaar and Hyzaar, $3 billion ...

Update -- Analysts See Potential Hurdles For Merck  -  Dec 6, 2006
Forbes,...said it expects sales of $3.7 billion to $4 billion for its Singulair respiratory drug, $3.1 billion to $3.4 billion for its Cozaar/Hyzaar hypertension drug ...

Merck Stand By Guidance, Cites Vaccines  -  Dec 6, 2006
Smartmoney.comMerck expects its Cozaar and Hyzaar drugs for hypertension to post sales of $3.1 billion to $3.4 billion in 2007, compared with $3 billion to $3.3 billion this ...

Merck Announces Strong Financial Results for the Third Quarter ...  Oct 20, 2006
Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR*, were $813 million for the third quarter, representing an increase of 8% from the third ... -Business Wire (press release), Merck, Schering-Plough shares climb  Oct 21, 2006
Sales rose 25 percent for asthma and allergy treatment Singulair, to $868 million, and 8 percent for blood pressure drugs Cozaar and Hyzaar, to $813 million. ... -Herald News Daily, Merck Mints Money  Oct 23, 2006
Merck's revenues. Singulair sales were up 25% worldwide to $868 million, and Cozaar and Hyzaar sales grew 8% to $813 million. But ... -Motley Fool Publicado: Sab Oct 14, 2006 5:01 pm Asunto: Unless directed to do ...  Oct 14, 2006
Even ad hyzaar lts are now realizing that theyre not "stupid, crazy or l ida zy", but that they have a recognized and treatab ibu e condition. ... -Shell Security, Research and Markets: Examine Financial Performance of Merck & Co ...  Oct 9, 2006
It was jointly developed with DuPont Merck (now Bristol-Myers Squibb), as was Hyzaar, a combination of Cozaar and hydrochlorothiazide. ... -Genetic Engineering News (press release), Do Not to Buy or Use Prescription Drugs from Various Canadian ...  Sep 18, 2006
...laboratory results to date have found counterfeits of the following drug products from these websites: Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (known ... -eMaxHealth.com

Online Prescription Intermediaries Provide Safe and Legitimate ...  Sep 20, 2006
The FDA tested Lipitor, Crestor, Celebrex, Zetia, Diovan, Hyzaar, Actonel, Nexium, Arimidex, and Propecia, and found they are counterfeit, according to Dr ... -PR Web

FDA Warns Against Some Online Orders Arimidex  Aug 31, 2006
The FDA says it’s investigating reports of counterfeit versions of several prescription drugs including Lipitor, Crestor, Zetia, Diovan, Hyzaar, and Actonel ... -Cancerpage.com

Canada's Mediplan Probed by US on Counterfeit Drugs (Update3)  Aug 30, 2006
The agency said it also found counterfeits of Merck's Hyzaar for high blood pressure and Propecia for baldness; Sanofi-Aventis SA and Procter & Gamble Co.'s ... -Bloomberg

Health and Science News Roundup  Aug 31, 2006
The fake drugs included versions of Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (known as Zetia in the United States), Crestor, Celebrex, Arimidex and ... -Monsters and Critics.com

FDA targets Canadian websites for counterfeit drugs  Aug 30, 2006
...that preliminary lab results of drugs intercepted through the provider found counterfeit versions of Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (Zetia ... -CBC Manitoba

FDA Warns Of Web Sites Selling Counterfeit Drugs  Aug 30, 2006
Preliminary laboratory results found counterfeits of the following drug products: Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol (known as Zetia in the ... -All Headline News

FDA Finds Counterfeits Among Prescription Drugs Ordered Through 10 ...  Aug 31, 2006
...from RxNorth.com, Canadiandrugstore.com and other Web sites -- were sold as Actonel, Arimidex, Crestor, Celebrex, Zetia, Diovan, Hyzaar, Lipitor, Nexium and ... -Kaiser network.org

Canadian Web Sites Selling Counterfeit Drug Products  Sep 1, 2006
...sites to be counterfeit: Lipitor (atorvastatin calcium), Diovan (valsartan), Actonel (risedronate sodium), Nexium (esomeprazole), Hyzaar (losartan potassium ... -Facts and Comparisons

Merck Remains Confident in Future Growth as it Executes on New ...  -  12 Dec 2006
Genetic Engineering News (press release),WORLDWIDE PRODUCT 2007 SALES SINGULAIR (Respiratory) $3.7 to $4.0 billion COZAAR/HYZAAR (Hypertension) $3.1 to $3.4 billion Vaccines (as recorded by Merck

Merck Backs FY06 EPS Outlook, Guides FY07; Reaffirms Plan To ...  -  Dec 6, 2006
Trading Markets,For 2006, the Merck expects worldwide sales of Singulair in the range of $3.4-$3.7 billion, sales of Cozaar/Hyzaar in the range of $3-$3.3 billion,

Merck & Co keeps profit forecasts conservative for 2007  -  Dec 7, 2006
Pharma Times (subscription),...$3.1-$3.4 billion for the antihypertensive Cozaar/Hyzaar (losartan); and $2.6-$2.9 billion for the osteoporosis drug Fosamax (alendronate).

Merck sees increase in profits for 2007  -  Dec 6, 2006
Ely Times,...$3.25 billion for companion blood pressure drugs Cozaar and Hyzaar, $3 billion for several vaccines, $2.8 billion for osteoporosis treatment Fosamax and

Update -- Analysts See Potential Hurdles For Merck  -  Dec 6, 2006
Forbes,...respiratory drug, $3.1 billion to $3.4 billion for its Cozaar/Hyzaar hypertension drug, and $2.6 billion to $2.9 billion for Osteoporosis drug Fosamax.

Merck backs forecast for year  -  Dec 6, 2006
MarketWatchIts Cozaar/Hyzaar hypertension drug is targeting $3 billion to $3.3 billion in 2006 sales, and 2007 sales $3.1 billion to $3.4 billion.

Merck Stand By Guidance, Cites Vaccines  -  Dec 6, 2006
Smartmoney.comMerck expects its Cozaar and Hyzaar drugs for hypertension to post sales of $3.1 billion to $3.4 billion in 2007, compared with $3 billion to $3.3 billion

Merck's chief leads a revival, but will it last?  -  Nov 13, 2006
Pittsburgh Post Gazette,...osteoporosis drug, will lose marketing exclusivity in 2008, followed by two other big sellers, hypertension treatments Cozaar and Hyzaar, in 2010.

Some Skin Products Up Cancer Risk  Aug 2, 2006
...blood pressure. Combination drugs, which contain HCTZ, include Maxide, Dyazide, Hyzaar, and Zestoretic. Antibiotics: Tetracycline ... -CBS News

Article by HairlossTalk.com  Aug 7, 2006
...percent to $490 million. Combined sales of newer hypertension drugs Cozaar and Hyzaar, rose 23 percent to $510 million. The drug giant ... -Hairloss Talk Newsletter

Merck 2Q profit more than doubles  Jul 25, 2006
30 percent to $950 million; Fosamax sales dipped slightly to $821 million; and sales for the related blood pressure medicines Cozaar and Hyzaar were flat at ... -Charlotte Observer

Teva's stock wounded in ongoing drug wars  Jun 22, 2006
This is the generic of Merck's Hyzaar to treat hypertension and reduce stroke risk in patients with left ventricle hypertrophy. ... -MSN Money



DuPont shifts focus off new discoveries  May 14, 2006
DuPont still earns substantial royalties and licensing income from Cozaar and sister drug Hyzaar — amounting to $747 million in 2005 — but the patents on ... - Wilkes Barre Times-Leader

Merck Announces Strong Financial Results for the First Quarter ...  Apr 20, 2006
Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR**, were $701 million for the first quarter, representing a decrease of 2% from the first ... - Business Wire

A Better Prognosis for Big Pharma  May 4, 2006
Merck unexpectedly lost Vioxx in 2004, and is set to lose patent protection on Zocor in 2006, on Fosamax in 2008, on Cozaar/Hyzaar in 2010, and on Singulair in ... - BusinessWeek

Merck Announces Strong Financial Results for the First Quarter ...  Apr 20, 2006
COZAAR/HYZAAR remainedthe number one branded AIIA in Europe and number two branded AIIA inthe United States in the first quarter. ... - Finanzen.net

Wait for More Bad News on Merck  Apr 20, 2006
...drug franchises. Cozaar/Hyzaar, Fosamax, and Zocor were all down, while Singulair had a reasonably good performance. Barring an ... - Motley Fool

Merck posts profit improvement  Apr 20, 2006
Quarterly sales of the company's asthma drug Singulair jumped 9% to $801 million, while sales of the hypertension therapies Cozaar and Hyzaar slipped 2% to ... - MarketWatch

DuPont's Profit Falls as Costs Rise, Seed Sales Drop (Update2)  Apr 25, 2006
Royalties from the hypertension drug Cozaar/Hyzaar, marketed through a venture with Merck & Co., boosted pharmaceuticals profit 6.3 percent to $169 million. ... - Bloomberg

Merck Q1 profits rise despite flat revenues  Apr 21, 2006
High blood pressure treatments Cozaar (losartan) and Hyzaar (losartan and hydrochlorothiazide) slipped 2% to $701 million, while osteoporosis drug Fosamax ... - Pharma Times (subscription)





DuPont invests in its Laurels  Apr 9, 2006
DuPont still earns substantial royalties and licensing income from Cozaar and sister drug Hyzaar - amounting to $747 million in 2005 - but the patents on those ... - Philadelphia Inquirer

Merck: The worst is yet to come?  Apr 6, 2006
...billion osteoporosis drug that loses patent protection in 2008, and Cozaar, which totaled $3 billion in 2005 when grouped with anti-hypertension drug Hyzaar. ... - CNNMoney.com

Merck gets split verdict for Vioxx  Apr 5, 2006
Vytorin and Zetia, also for high cholesterol * Fosamax, top osteoporosis treatment * Singulair, for asthma and allergies * Cozaar and Hyzaar, for high blood ... - News & Observer

French biotech NicOx's shares soar on Merck deal  Mar 21, 2006
...disorders. Merck already sells the blood-pressure drugs Cozaar and Hyzaar, which had combined sales of $3 billion in 2005. Shares ... - Investor's Business Daily (subscription)

DuPont Lifts Near-Term Expectations  Mar 15, 2006
...exposure to the struggling auto industry, erosion of Pioneer corn seed's market share and the 2010 expiration of patents on hypertension drugs Cozaar/Hyzaar. ... - Smartmoney.com

Zacks.com Announces That Kelley Wright Highlights the Following ...  Mar 15, 2006
Zocor's exclusivity in the United States will end in June of this year. Complimenting Zocor is Cozaar/Hyzaar which is designed to help treat hypertension. ... - Business Wire



DuPont expects profit drop as drug goes off patent in 2010  Feb 15, 2006
DuPont Co. will see a rapid drop in profits from hypertension drug Cozaar/Hyzaar starting in 2010, Chief Executive Officer Charles O. Holliday Jr. ... - The News Journal,

Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ...  Jan 31, 2006
Global sales of Merck's antihypertensive medicines, COZAAR and HYZAAR**, were $782 million for the fourth quarter, representing growth of 2% over fourth ... - TMCnet

Merck Marking Time  Jan 31, 2006
There was good growth from Singulair, but most of the other large drugs, including Cozaar/Hyzaar, Fosamax, and Zocor, saw sales either barely up (2% growth for ... - Motley Fool

Merck Earnings Top Estimates  Jan 31, 2006
Among major drugs, fourth-quarter sales of asthma treatment Singulair rose 12% to $819 million; sales of blood-pressure drugs Cozaar and Hyzaar rose 2% to $782 ... - TheStreet.com

DuPont Shares Look 'Deceptively Cheap'  Jan 12, 2006
Rita, research analyst Kevin McCarthy said he remains cautious on DuPont due to the company's patent expirations for hypertension drugs Cozaar and Hyzaar and a ... - Forbes

Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ...  Jan 31, 2006
...year 2004. COZAAR and HYZAAR belong to the AIIA class, which remains thefastest growing class in the antihypertensive market. COZAAR ... - Finanzen.net

DuPont "neutral," target price reduced  Jan 13, 2006
DuPont’s Cozaar/Hyzaar pharma patents are scheduled to expire in 2010, the analyst says. The EPS estimate for 2006 has been reduced from $2.75 to $2.30. - New Ratings

Merck results better than expected  Jan 31, 2006
Sales of asthma and allergy treatment Singulair rose 12 percent to $819 million, while sales of hypertension treatment Cozaar/Hyzaar rose 2 percent to $782 ... - Reuters

Merck profit slightly higher, beats forecasts  Jan 31, 2006
Combined sales of hypertension treatments Cozaar and Hyzaar rose just 2 percent to $782 million, and sale of osteoporosis treatment Fosamax fell 5 percent to ... - Reuters

DuPont earnings dip 45%  Jan 25, 2006
DuPont received royalties of $203 million from sales of Cozaar and Hyzaar, a pair of drugs for treating high blood pressure it licenses to Merck & Co. ... - The News Journal

Merck profit beats estimates, sales rise to $5.77 bln  Jan 31, 2006
...million from last year. Combined sales of its Cozaar/Hyzaar blood pressure drug franchise rose 2% to $782 million. The company's top ... - Investor's Business Daily (subscription)

Merck profits edge ahead in fourth quarter  Feb 1, 2006
Merck's blood pressure treatment range, headed by Cozaar (losartan) and Hyzaar (losartan and hydrochlorothiazide), advanced 2% to $782 million in the fourth ... - Pharma Times (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional